MetLife Investment Management’s Century Therapeutics IPSC Stock Holding History

MetLife Investment Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$187K	Buy	+76,271	New	+$174K	﹤0.01%	2451
2023 Q1	–	Sell	-12,167	Closed	-$62.4K	–	2806
2022 Q4	$62.4K	Hold	12,167	–	–	﹤0.01%	2729
2022 Q3	$120K	Hold	12,167	–	–	﹤0.01%	2584
2022 Q2	$102K	Hold	12,167	–	–	﹤0.01%	2707
2022 Q1	$153K	Buy	+12,167	New	+$161K	﹤0.01%	2506
2021 Q4	–	Sell	-4,939	Closed	-$124K	–	2526
2021 Q3	$124K	Buy	+4,939	New	+$134K	﹤0.01%	2344

Other funds holding IPSC

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

MetLife Investment Management's IPSC Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Century Therapeutics (IPSC) in Q2 2026: 76,271 shares worth $187K. The stake represents ﹤0.01% of the portfolio and ranks #2451 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in IPSC as recently as Q4 2022.

MetLife Investment Management first reported a position in IPSC in Q3 2021 and has held it in 6 quarters since. 100 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

MetLife Investment Management held 76,271 shares of Century Therapeutics worth $187K as of Q2 2026.
Century Therapeutics was a new MetLife Investment Management position in Q2 2026.
Century Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2451 holding.
MetLife Investment Management first reported a position in Century Therapeutics in Q3 2021 and has held it in 6 quarters since.
100 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.